ArticleBreast cancer research and treatment2022
Coagulation/fibrinolysis and circulating tumor cells in patients with advanced breast cancer.
Article in Breast cancer research and treatment, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Prediction of non-sentinel lymph node metastasis using the clinical features of thrombin time under the status of 1-2 positive sentinel lymph node of breast cancer.Future oncology (London, England) · 2026Article
- Emerging roles of haemostatic proteins as markers of disease progression and prognosis in breast cancer.Exploration of targeted anti-tumor therapy · 2026Review
- Regular aspirin use, breast tumor characteristics and long-term breast cancer survival.NPJ breast cancer · 2025Article
- D-dimer predicts the response of patients with gastric cancer to first-line immunotherapy combined with chemotherapy.Journal of gastrointestinal oncology · 2025Article
- Coagulation profiles of breast cancer patients attending at cancer treatment centres in Northwest Ethiopia 2023: a comparative cross-sectional study.Scientific reports · 2025Article
- A coagulation-related long non-coding RNA signature to predict prognosis and immune features of breast cancer.Discover oncology · 2025Article
- Neutrophil Extracellular Traps Enhance Procoagulant Activity and Predict Poor Prognosis in Patients With Metastatic Breast Cancer.International journal of general medicine · 2025Article
- Advances and potentials in platelet-circulating tumor cell crosstalk.American journal of cancer research · 2025Review
- Risk prediction of mechanical complications in acute myocardial infarction patients with prior malignancy.Frontiers in pharmacology · 2025Article
- Diagnostic and Predictive Recurrence Value of Plasma Fibrinogen in Patients With Adrenocortical Carcinoma.Clinical Medicine Insights. Oncology · 2025Article
- Using heart rate variability to evaluate the association between the autonomic nervous system and coagulation function in patients with endometrial cancer.Oncology letters · 2024Article
- Article
- A new prognostic model for glioblastoma multiforme based on coagulation-related genes.Translational cancer research · 2023Article
- Clinical Validation of a Size-Based Microfluidic Device for Circulating Tumor Cell Isolation and Analysis in Renal Cell Carcinoma.International journal of molecular sciences · 2023Article
- A novel classifier combining G protein-coupled receptors and the tumor microenvironment is associated with survival status in glioblastoma.Frontiers in pharmacology · 2023Article
- Predictive Nomogram for Hyperprogressive Disease During Anti-PD-1/PD-L1 Treatment in Patients with Advanced Non-Small Cell Lung Cancer.ImmunoTargets and therapy · 2023Article
- Pulmonary Tumor Thrombotic Microangiopathy in a Patient with Rapid Progressive Triple-Negative Breast Cancer.Case reports in oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the relationship between circulating tumor cells (CTCs) and standard coagulation tests in both a discovery and a validation cohort of patients with advanced breast cancer.
methodsIn a retrospective (n = 77) and a prospective (n = 92) study of patients with progressive advanced breast cancer, CTC count, platelet number, fibrinogen level, D-dimers, prothrombin time, and activated partial thromboplastin time were measured. The association between these coagulation studies and CTC count was analyzed. The impact of these measurements on overall survival (OS) was assessed.
resultsIn both cohorts, results were similar; absolute CTC count was significantly associated to D-dimer level and inversely with platelet count. In the prospective cohort, quantification of tumor-derived extracellular vesicles (tdEVs) was associated with CTC count, and with coagulation abnormalities (low platelet count and increased D-dimers). tdEVs did not add to CTC count in predicting changes in platelets or D-dimers. In multivariate analysis only CTC ≥ 5 CTC/7.5 mL, ER status, HER2 status and lines of chemotherapy were associated with OS. In patients with terminally metastatic breast cancer, very high CTC counts are prevalent.
conclusionA significant association exists between increasing CTC number and increased D-dimers and decreased platelet counts, suggesting a potential role for CTCs as a direct contributor of intravascular coagulation activation. In patients with advanced and progressive breast cancer, abnormalities in routine coagulation tests is the rule. In patients with terminally advanced breast cancer a "leukemic" phase with high CTC count is prevalent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.